This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring
March 18–20, 2024 | Barcelona, SpainMarch 26–27, 2024 | Digital Partnering

Synaffix BV


Synaffix BV is a Dutch biotech company that has established a proprietary, clinical-stage antibody-drug conjugate (ADC) technology platform that delivers best-in-class safety and efficacy profiles compared to all 3 major clinical-stage ADC technologies.
Over $9.0 billion in technology out-licensing deals with renowned partners like Shanghai Miracogen, Mersana Therapeutics, ADC Therapeutics, Innovent Biologics, Profound Bio, Kyowa Kirin Co., Genmab, Janssen (in collaboration with Mersana) and more recently, Hummingbird Bioscience, Chong Kun Dang Pharm, Amgen, Macrogenics, ABL Bio and Sotio validate our approach.
The business model of Synaffix is technology out-licensing where we regularly engage in research collaborations with companies that are interested in developing highly competitive ADC Products using our proprietary technology.